Podium to Practice: Chicago 2026 – LUNG: CHRYSALIS-2 study
OR
Studies / Trials Discussed
8501 – Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
8501 – Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.